MedTrace Logo

Study of Etacoat in Patients With Cataract Surgery Via the Anterior Chamber

NCT03644875 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-12-10

No results posted yet for this study

Summary

This is a prospective, single center, non-comparative, 90-day follow-up, post-market clinical investigation of etacoat in patients undergoing cataract surgery.

The performance is evaluated by the preservation of endothelial cells measured by specular microscopy at the follow-up visit in comparison to baseline values.

Conditions

  • Cataract Surgery

Interventions

DEVICE

etacoat

Etacoat is a HPMC formulation intended to be used in ophthalmic anterior segment cataract surgery.

Sponsors & Collaborators

  • Croma-Pharma GmbH

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-28
Primary Completion
2019-05-16
Completion
2019-05-16

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03644875 on ClinicalTrials.gov